General Information of This Drug (ID: DM6JXWL)

Drug Name
Sagopilone   DM6JXWL
Synonyms
Sagopilone; ZK-EPO; 305841-29-6; UNII-KY72JU32FO; KY72JU32FO; DE-03757; ZK-219477; EPO-477; SH-Y03757A; ZK epothilone; Sagopilone [USAN:INN]; Sagopilone (USAN/INN); SCHEMBL423579; CHEMBL2304041; SH Y03757A; Bay 86-5302; ZINC3964449; DB12391; SH-Y-03757; BAY-86-5302; AN-28960; DE 03757; ZK 219477; D09721; 841S296; (1S,3S,7S,10R,11S,12S,16R)-10-allyl-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Breast cancer DIS7DPX1 2C60-2C65 Phase 2 [1]
Ovarian cancer DISZJHAP 2C73 Phase 2 [1]
Prostate cancer DISF190Y 2C82.0 Phase 2 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00598507) Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma. U.S. National Institutes of Health.